MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

MOLECULAR PARTNERS AG

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 12, 2026

$3.66+0.10 (+2.81%)

Close on Oct 19, 2026

MOLECULAR PARTNERS AG income statement

Annual QuarterlyTTM

CHF USD

Millions of CHF, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	0	4.97	7.04	190	9.75	9.34	20
Research & Development	40	49	49	51	56	56	43
Selling, General & Admin	15	18	19	22	17	12	14
Operating Expenses	58	66	68	73	73	68	57
Operating Income	-58	-61	-61	117	-63	-58	-37
Interest Expense	5.05	0.04	5.16	0.62	0.56	4.82	1.21
Interest & Investment Income	1.52	7.21	4.28	1.86	0.19	0.37	1.60
Pretax Income	-62	-54	-62	118	-64	-63	-36
Income Tax Expense	0.00	0.00	0	0	0.00	-0.01	0.02
Net Income incl. Noncontrolling Interests	-62	-54	-62	118	-64	-63	-36
EPS (Basic)(per share)	-1.65	-1.59	-1.89	3.63	-2.06	-2.51	-1.69
EPS (Diluted)(per share)	-1.65	-1.59	-1.89	3.54	-2.06	-2.51	-1.69
Shares Outstanding (Basic, Weighted)(shares)	37	34	33	32	31	25	21
Shares Outstanding (Diluted, Weighted)(shares)	37	34	33	33	31	25	21
EBITDA	-56	-59	-59	119	-61	-55	-34

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 8.79
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 749.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.